UY39582A - VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARSCOV-2 AND/OR THE PREVENTION OF SARSCOV-2 RELATED CORONAVIRUS INFECTION - Google Patents

VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARSCOV-2 AND/OR THE PREVENTION OF SARSCOV-2 RELATED CORONAVIRUS INFECTION

Info

Publication number
UY39582A
UY39582A UY0001039582A UY39582A UY39582A UY 39582 A UY39582 A UY 39582A UY 0001039582 A UY0001039582 A UY 0001039582A UY 39582 A UY39582 A UY 39582A UY 39582 A UY39582 A UY 39582A
Authority
UY
Uruguay
Prior art keywords
sarscov
induction
prevention
aav5
cov
Prior art date
Application number
UY0001039582A
Other languages
Spanish (es)
Inventor
Pavel Mikhailovich Gershovich
Alexander Vladimirovich Prokofyev
Anna Nikolaevna Strelkova
Natalia Aleksandrovna Spirina
Tatiana Evgenievna Shugaeva
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of UY39582A publication Critical patent/UY39582A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invención refiere a un dominio de unión a receptor recombinante aislado de la glicoproteína S (RBD-S) de SARS-CoV-2, a un ácido nucleico que codifica RBD-S de SARS-CoV-2, a un casete de expresión y un vector basado en el mismo, a un virus basado en AAV5 recombinante (virus adenoasociado serotipo 5) para la inducción de inmunidad específica al SARS-CoV-2 y / o la prevención de dicha infección, a un AAV5 - vacuna basada en la inducción de inmunidad específica al SARS-CoV-2 y / o prevención de la infección por coronavirus relacionada con el SARS-CoV-2.This invention relates to an isolated recombinant receptor binding domain of glycoprotein S (RBD-S) of SARS-CoV-2, to a nucleic acid encoding RBD-S of SARS-CoV-2, to an expression cassette and a vector based on the same, to a virus based on recombinant AAV5 (adeno-associated virus serotype 5) for the induction of specific immunity to SARS-CoV-2 and / or the prevention of said infection, to an AAV5 - induction-based vaccine of specific immunity to SARS-CoV-2 and/or prevention of SARS-CoV-2 related coronavirus infection.

UY0001039582A 2020-12-21 2021-12-21 VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARSCOV-2 AND/OR THE PREVENTION OF SARSCOV-2 RELATED CORONAVIRUS INFECTION UY39582A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020142220A RU2760301C1 (en) 2020-12-21 2020-12-21 Aav5-based vaccine for induction of specific immunity to sars-cov-2 virus and/or prevention of coronavirus infection caused by sars-cov-2

Publications (1)

Publication Number Publication Date
UY39582A true UY39582A (en) 2022-05-31

Family

ID=78719331

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039582A UY39582A (en) 2020-12-21 2021-12-21 VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARSCOV-2 AND/OR THE PREVENTION OF SARSCOV-2 RELATED CORONAVIRUS INFECTION

Country Status (4)

Country Link
AR (1) AR124461A1 (en)
RU (1) RU2760301C1 (en)
UY (1) UY39582A (en)
WO (1) WO2022139631A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117210457A (en) * 2022-06-10 2023-12-12 拜奥卡德联合股份公司 Nucleic acid having promoter activity and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112023035A (en) * 2020-04-07 2020-12-04 中国医学科学院医学生物学研究所 Nano vaccine taking S protein RBD region of SARS-CoV-2 virus as antigen and preparation thereof
RU2723008C9 (en) * 2020-05-19 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Method for producing chinese hamster ovary cell strain, producer of sars-cov-2 virus recombinant rbd protein, chinese hamster ovary cell strain, producer of recombinant rbd protein of sars-cov-2 virus, method of producing recombinant rbd protein of sars-cov-2 virus, a test system for enzyme-linked immunosorbent assay of human blood serum or plasma and its use
CN111560354B (en) * 2020-05-22 2022-07-19 中国人民解放军总医院第五医学中心 Recombinant novel coronavirus, preparation method and application thereof
RU2733832C1 (en) * 2020-07-28 2020-10-07 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Artificial gene stbl_rbd_trm_sc2, coding a bicistronic structure formed by the sars-cov-2 coronavirus glycoprotein s receptor-binding domain sequences, transmembrane region, p2a-peptide and glycoprotein g vsv, recombinant plasmid pstem-rvsv-stbl_rbd_trm_sc2, providing expression of artificial gene, and a recombinant strain of vesicular stomatitis virus rvsv-stbl_rbd_trm_sc2, used to create a vaccine against sars-cov-2 coronavirus

Also Published As

Publication number Publication date
RU2760301C1 (en) 2021-11-23
WO2022139631A1 (en) 2022-06-30
AR124461A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
BR112022009895A2 (en) MICRODYSTROPHIN GENE THERAPY CONSTRUCTS AND USES THEREOF
MX2023000411A (en) Sars-cov-2 and influenza combination vaccine.
CY1119052T1 (en) NEW PHARMACEUTICAL FORMS OF VACCINE INCLUDING SAPONIN CONTAINING IMMUNE
PE20181168A1 (en) VARIANTS OF FACTOR VIII REDUCED WITH CpG, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF DISORDERS OF HEMOSTASIA
BR112022016346A2 (en) VACCINE NCOV-2019 (SARS-COV-2)
UY39582A (en) VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARSCOV-2 AND/OR THE PREVENTION OF SARSCOV-2 RELATED CORONAVIRUS INFECTION
UY39396A (en) VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARSCOV-2 AND/OR THE PREVENTION OF SARSCOV-2 RELATED CORONAVIRUS INFECTION
EA201170812A1 (en) METHODS AND COMPOSITIONS FOR USING A VACCINE AGAINST COCKDIOSIS
BR112012031211A2 (en) methods and vaccine to reduce campylobacter infection
MX2021012311A (en) Variant aav capsids for intravitreal delivery.
PE20230171A1 (en) VACCINES AGAINST CORONAVIRUS AND METHODS OF USE
CO2017001614A2 (en) Recombinant vector vaccine for avian adenovirus serotype 9
BR112022022604A2 (en) RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SARS-COV-2 SPIKE PROTEIN AND ITS USES
BR112022000865A2 (en) African swine fever vaccine
BR112018068890A2 (en) dna marine polymerases
BRPI0920622A8 (en) African equine disease virus vaccine
MX2021000949A (en) New attenuated virus strain and use thereof as a vaccine.
MX9304349A (en) NON-VIRULENT ANTIRRABIC VACCINE.
MX2022015489A (en) A recombinant modified vaccinia virus ankara (mva) vaccine against coronavirus disease.
ATE493146T1 (en) IGF-1 AS A VACCINE AID FOR CATS, PARTICULARLY AGAINST FELINE RETROVIRUSES
BR112022022263A2 (en) TREATMENT OF VIRAL INFECTIONS
BR112022024911A2 (en) MATERIALS AND METHODS FOR INHIBITING A VIRAL INFECTION, INCLUDING A CORONA VIRUS INFECTION
BR112022016604A2 (en) COMPOUNDS FOR USE IN VIRAL INFECTIONS
BR112021026193A2 (en) Compositions and methods for treating or preventing eye infections with filociclovir
BR112021026616A2 (en) Exenatide compositions for pulmonary administration and use thereof